Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
1995-06-07
2002-03-19
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C530S300000, C530S350000
Reexamination Certificate
active
06358510
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to intercellular adhesion molecules such as ICAM-1 which are involved in the process through which populations of lymphocytes recognize and adhere to cellular substrates so that they may migrate to sites of inflammation and interact with cells during inflammatory reactions. The present invention additionally relates to ligand molecules capable of binding to such intercellular adhesion molecules, to a screening assay for these ligands, and to uses for the intercellular adhesion molecule, the ligand molecules, and the screening assay.
2. Description of the Related Art
Leukocytes must be able to attach to cellular substrates in order to properly defend the host against foreign invaders such as bacteria or viruses. An excellent review of the defense system is provided by Eisen, H. W., (
In: Microbiology
, 3rd Ed., Harper & Row, Philadelphia, Pa. (1980), pp. 290-295 and 381-418). They must be able to attach to endothelial cells so that they can migrate from circulation to sites of ongoing inflammation. Furthermore, they must attach to antigen-presenting cells so that a normal specific immune response can occur, and finally, they must attach to appropriate target cells so that lysis of virally-infected or tumor cells can occur.
Recently, leukocyte surface molecules involved in mediating such attachments were identified using hybridoma technology. Briefly, monoclonal antibodies directed against human T-cells (Davignon, D. et al.,
Proc. Natl. Acad. Sci. USA
78:4535-4539 (1981)) and mouse spleen cells (Springer, T. et al.
Eur. J. Immunol
. 9:301-306 (1979)) were identified which bound to leukocyte surfaces and inhibited the attachment related functions described above (Springer, T. et al.,
Fed. Proc
. 44:2660-2663 (1985)). The molecules identified by those antibodies were called Mac-1 and Lymphocyte Function-associated Antigen-1 (LFA-1). Mac-1 is a heterodimer found on macrophages, granulocytes and large granular lymphocytes. LFA-1 is a heterodimer found on most lymphocytes (Springer, T. A., et al.
Immunol. Rev
. 68:111-135 (1982)). These two molecules, plus a third molecule, p150,95 (which has a tissue distribution similar to Mac-1) play a role in cellular adhesion (Keizer, G. et al.,
Eur. J. Immunol
. 15:1142-1147 (1985)).
The above-described leukocyte molecules were found to be members of a related family of glycoproteins (Sanchez-Madrid, F. et al.,
J. Exper. Med
. 158:1785-1803 (1983); Keizer, G. D. et al.,
Eur. J. Immunol
. 15:1142-1147 (1985)). This glycoprotein family is composed of heterodimers having one alpha chain and one beta chain. Although the alpha chain of each of the antigens differed from one another, the beta chain was found to be highly conserved (Sanchez-Madrid, F. et al.,
J. Exper. Med
. 158:1785-1803 (1983)). The beta chain of the glycoprotein family (sometimes referred to as “CD18”) was found to have a molecular weight of 95 kd whereas the alpha chains were found to vary from 150 kd to 180 kd (Springer, T.,
Fed. Proc
. 44:2660-2663 (1985)). Although the alpha subunits of the membrane proteins do not share the extensive homology shared by the beta subunits, close analysis of the alpha subunits of the glycoproteins has revealed that there are substantial similarities between them. Reviews of the similarities between the alpha and beta subunits of the LFA-1 related glycoproteins are provided by Sanchez-Madrid, F. et al., (
J. Exper. Med
. 158:586-602 (1983);
J. Exper. Med
. 158:1785-1803 (1983)).
A group of individuals has been identified who are unable to express normal amounts of any member of this adhesion protein family on their leukocyte cell surface (Anderson, D. C., et al.,
Fed. Proc
. 44:2671-2677 (1985); Anderson, D. C., et al.,
J. Infect. Dis
. 152:668-689 (1985)). Lymphocytes from these patients displayed in vitro defects similar to normal counterparts whose LFA-1 family of molecules had been antagonized by antibodies. Furthermore, these individuals were unable to mount a normal immune response due to an inability of their cells to adhere to cellular substrates (Anderson, D. C., et al.,
Fed. Proc
. 44:2671-2677 (1985); Anderson, D. C., et al.,
J. Infect. Dis
. 152:668-689 (1985)). These data show that immune reactions are mitigated when lymphocytes are unable to adhere in a normal fashion due to the lack of functional adhesion molecules of the LFA-1 family.
Thus, in summary, the ability of lymphocytes to maintain the health and viability of an animal requires that they be capable of adhering to other cells (such as endothelial cells). This adherence has been found to require cell-cell contacts which involve specific receptor molecules present on the cell surface of the lymphocytes. These receptors enable a lymphocyte to adhere to other lymphocytes or to endothelial, and other non-vascular cells. The cell surface receptor molecules have been found to be highly related to one another. Humans whose lymphocytes lack these cell surface receptor molecules exhibit chronic and recurring infections, as well as other clinical symptoms including defective antibody responses.
Since lymphocyte adhesion is involved in the process through which foreign tissue is identified and rejected, an understanding of this process is of significant value in the fields of organ transplantation, tissue grafting, allergy and oncology.
SUMMARY OF THE INVENTION
The present invention relates to Intercellular Adhesion Molecule-1 (ICAM-1) as well as to its functional derivatives. The invention additionally pertains to antibodies and fragments of antibodies capable of inhibiting the function of ICAM-1, and to other inhibitors of ICAM-1 function; and to assays capable of identifying such inhibitors. The invention additionally includes diagnostic and therapeutic uses for all of the above-described molecules.
In detail, the invention includes the intercellular adhesion molecule ICAM-1 or its functional derivatives, which are substantially free of natural contaminants. The invention further pertains to such molecules which are additionally capable of binding to a molecule present on the surface of a lymphocyte.
The invention further pertains to the intercellular adhesion molecule ICAM-1, and its derivatives which are detectably labeled.
The invention additionally includes a recombinant DNA molecule capable of expressing ICAM-1 or a functional derivative thereof.
The invention also includes a method for recovering ICAM-1 in substantially pure form which comprises the steps:
(a) solubilizing ICAM-1 from the membranes of cells expressing ICAM-1, to form a solubilized ICAM-1 preparation,
(b) introducing the solubilized ICAM-1 preparation to an affinity matrix, the matrix containing antibody capable of binding to ICAM-1,
(c) permitting the ICAM-1 to bind to the antibody of the affinity matrix,
(d) removing from the matrix any compound incapable of binding to the antibody and
(e) recovering the ICAM-1 in substantially pure form by eluting the ICAM-1 from the matrix.
The invention additionally includes an antibody capable of binding to a molecule selected from the group consisting of ICAM-1 and a functional derivative of ICAM-1. The invention also includes a hybridoma cell capable of producing such an antibody.
The invention further includes a hybridoma cell capable of producing the monoclonal antibody R6-5-D6.
The invention further includes a method for producing a desired hybridoma cell that produces an antibody which is capable of binding to ICAM-1, which comprises:
(a) immunizing an animal with a cell expressing ICAM-1,
(b) fusing the spleen cells of the animal with a myeloma cell line,
(c) permitting the fused spleen and myeloma cells to form antibody secreting hybridoma cells, and
(d) screening the hybridoma cells for the desired hybridoma cell that is capable of producing an antibody capable of binding to ICAM-1.
The invention includes as well the hybridoma cell, and the antibody produced by the hybridoma cell, obtained by the above method.
The invention is also directed to a method of identifyi
Dustin Michael L.
Marlin Steven D.
Rothlein Robert
Springer Timothy A.
Dana Farber Cancer Institute
Gambel Phillip
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
ICAM-1 derivatives with altered ability to bind LFA-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ICAM-1 derivatives with altered ability to bind LFA-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ICAM-1 derivatives with altered ability to bind LFA-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2842028